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Recent  literature  indicates  that mice  deﬁcient  in the  chemokine  receptor  CCR9  (CCR9−/− mice)  are unable
to  generate  oral  tolerance.  The  present  report  describes  how  such  inability  can  be  overcome  by increasing
the  dose  of oral  antigen.  Pharmacological  inhibition  of  CCR9  did  not  affect  the  generation  of oral  tolerance,
regardless  of antigen  dose.  These  results  highlight  the  inadequacy  of genetic  deletion  of CCR9  whenccepted  7 January 2013
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predicting  the  effects  of  pharmacological  CCR9  inhibition  on  intestinal  biology.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction
CCR9 is expressed on leukocytes, including T cells [1], B cells [1]
nd dendritic cells (DC) [2], and plays a central role in their migra-
ion to the intestines and thymus. CCL25, the only known ligand
or CCR9, is expressed by intestinal and thymic epithelial cells [3].
ndeed, interference with the CCR9/CCL25 axis results in decreased
ntigen-speciﬁc T cell recruitment to the intestine [4]. CCR9 expres-
ion has also been reported on immature plasmacytoid dendritic
ells (pDC), which play a role in the generation of immune tolerance
5]. Cassani et al. [6] reported that CCR9−/− mice had a diminished
apacity to generate immune tolerance to oral antigens. Results
rom the recent PROTECT-1 clinical trial in Crohn’s disease showed
hat the CCR9 antagonist CCX282-B (vercirnon) was well tolerated
nd efﬁcacious [7]. Previously, treatment with the CCR9 antagonist
CX282-B was shown to be therapeutic in the TNF-ARE mouse
odel of ileitis [8]; however, CCR9−/− TNF-ARE mice displayed
 different phenotype than those treated with compound [9,10].
ecause of these known differences between genetic deletion and
harmacological inhibition, the ability of a CCR9 antagonist to mod-
late immune tolerance to oral antigen was tested.∗ Corresponding author. Tel.: +1 650 210 2900; fax: +1 650 210 2974.
E-mail  address: mwalters@chemocentryx.com (M.J. Walters).
1 All the authors are employees and stock holders of ChemoCentryx.
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All  animal experiments were approved by the ChemoCentryx
Institutional Animal Care and Use Committee. Adoptive transfer
and oral tolerance experiments are outlined in Figs. 1A and 2A,
respectively. CCR9−/− mice were obtained, under license, from Dr.
Paul Love at the National Institute for Health. CCX507 was sup-
plied by the Medicinal Chemistry Department at ChemoCentryx
(Mountain View, CA). The effectiveness of CCX507 to block in vivo
migration of antigen speciﬁc T cells to the small intestine was deter-
mined using an adoptive transfer model based on the methods
outlined by Wurbel et al. [4]. T cells were isolated from CD45.2+
OT-1 mice and adoptively transferred into CD45.1+ mice. 24 h post
transfer, mice were dosed with CCX507 or vehicle, and then orally
challenged 1 h later with ovalbumin (OVA, Sigma, St. Louis, MI)
alone or in combination with cholera toxin (Ctx; EMD Millipore, Bil-
lerica, MA). The small intestine was harvested 4 days later and the
intraepithelial lymphocytes (IEL) isolated. IELs were stained with
propidium iodide, CD45.2, CD45.1 and CD8 (BD Biosciences, San
Jose, CA). The frequency of CD8+ CD45.2+ PI- cells was determined
in each IEL sample.
Oral  tolerance was  induced by orally dosing C57BL/6 mice with
either 2.5 mg/day or 25 mg/day of OVA in PBS for 5 consecutive
days. Mice orally dosed with PBS only were used as controls. All
mice were immunized with 200 g OVA/complete Freund’s adju-
vant (CFA, Chondrex, Redmond, WA)  emulsion (250 g OVA in
saline plus 100 l CFA) on day 7. On day 14, mice were challenged
intradermally with OVA (500 ng) in the right ear and with saline in
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Fig. 1. Pharmacological blockade of CCR9 results in a signiﬁcant reduction in T cell recruitment to the intestine. (A) Protocol for adoptive transfer model. (B) Adoptive transfer
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if  CD45.2+ OT-1 T cells and subsequent challenge of recipient mice with OVA plus 
black bar). Antagonism of CCR9 with CCX507 (30 mg/kg;blue bar) signiﬁcantly red
open  bar). n = 5–10 animals per group, representative data shown from 2 separate 
he left ear (Fig. 1A). Speciﬁc delayed type hypersensitivity (DTH)
as calculated as the difference in thickness between the right
nd left ears 24 h post challenge. Although the earlier report [6]
lso utilized a DTH reaction as a measure of immune tolerance, the
natomical location used, the footpad, is different from that used in
hese studies. CCX507 (30 or 300 mg/kg) or vehicle was  given prior
o the ﬁrst oral OVA exposure and dosed daily throughout the oral
VA challenges.
.  Results and discussion
The  ability of the CCR9 antagonist CCX507 to block antigen-
peciﬁc in vivo T cell migration was conﬁrmed using an adoptive
ransfer model (Fig. 1A) [4]. Recipient mice challenged with
VA:CTx exhibited a signiﬁcant increase in CD8+ CD45.2+ OT-1
ell frequency in the small intestine relative to mice challenged
ith OVA alone (Fig. 1B, p = 0.01). CCX507 (30 mg/kg) signiﬁcantly
educed the frequency of CD45.2+ IEL in mice challenged with
VA:CTx (Fig. 1B, p = 0.002).
In  studies to determine the effect of CCR9 inhibition on the gen-ration of immune tolerance to oral antigens, C57BL/6 mice that
eceived either 2.5 mg/day or 25 mg/day of oral OVA developed the
xpected systemic tolerance, as indicated by a signiﬁcant decrease
n antigen-speciﬁc ear swelling upon re-challenge (Fig. 2B and C;sults in a signiﬁcant increase in CD45.2+ cell frequency within the small intestine
ccumulation of CD45.2+ cells to levels equal to animals challenged with OVA  only
iments. **p < 0.01 Mann Whitney test vs. appropriate control.
p < 0.01 for both OVA groups vs. saline control). Consistent with the
earlier report [6], CCR9−/− mice receiving 2.5 mg/day oral OVA did
not develop systemic tolerance to OVA, as evidenced by the ear
swelling response upon re-challenge (Fig 2B; no signiﬁcant differ-
ence relative to control). However, challenge of CCR9−/− mice with
25 mg/day oral OVA resulted in the generation of systemic toler-
ance upon re-challenge (Fig. 2C; p = 0.007 vs. saline control CCR9−/−
mice). Inhibition of CCR9 with CCX507 (30 mg/kg) dosed during the
oral antigen challenge phase did not alter the ability of mice to gen-
erate immune tolerance to either dose of oral OVA (Fig. 2D and E;
p < 0.05 vs. saline control). Additional experiments were conducted
in which CCX507 (30 mg/kg) was  dosed prior to the initial antigen
exposure and throughout the remainder of the experiment; the
same experimental setup was  also tested using 300 mg/kg CCX507.
In both cases inhibition of CCR9 did not result in any detectable
deﬁciencies in the ability of these mice to develop normal immune
tolerance to orally administered antigen (Fig, 2F and G; p < 0.05 vs.
saline control).
Genetic deletion of drug targets in mice can result in phen-
otypes that differ from those obtained with pharmacological
blockade of the same target in adult animals. One such example
is CCR4, in which the oxazolone-induced allergic inﬂammation is
exacerbated in CCR4−/− mice [11], while pharmacological inter-
vention with a CCR4 antagonist results in signiﬁcant therapeutic
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Fig. 2. Genetic deletion of CCR9 does not predict the outcome of pharmacological inhibition of CCR9. (A) Protocol for oral tolerance model (B) WT C57BL/6 or CCR9−/− mice
that did not receive oral OVA had a robust DTH response to OVA challenge. In contrast to WT C57BL/6, CCR9−/− mice that received 2.5 mg/day tolerizing OVA dose did not
develop immune tolerance to OVA. (C) CCR9−/− mice that received 25 mg/day tolerizing OVA dose developed normal immune tolerance. (D and E) 30 mg/kg CCX507 dosed
during the oral antigen priming did not impair the generation of oral tolerance at either dose of tolerizing antigen. (F and G) 30 or 300 mg/kg CCX507 dosed throughout the
entire  study did not impair the generation of oral tolerance at either dose of tolerizing antigen. *p < 0.05; **p < 0.01; Mann Whitney test vs. appropriate saline control animals.
Data shown is from one experiment (n = 5 animals per groups), all experiments were repeated on 2 separate occasions.
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mprovement [12]. Recent publications [10,13] using CCR9−/− mice
ave concluded that genetic deletion of CCR9 may  lead to dis-
ase exacerbation or to deﬁciencies in generation of tolerance to
ral antigen. The present work demonstrates that the inability
f CCR9−/− mice to generate immune tolerance can be overcome
y increasing the tolerizing antigen dose. In stark contrast to
enetic deletion of CCR9, pharmacological inhibition of CCR9 does
ot impair the generation of immune tolerance to oral antigen,
egardless of antigen dose. Thus, caution should be exercised when
ssuming that phenotypes associated with deletion of CCR9, and
erhaps other chemokine receptors, are faithful predictors of bio-
ogical effects that might results from pharmacological inhibition
f such receptors. This is perhaps not surprising given the differ-
nces, relative to wild type mice, in steady state T cell [14] and pDC
2] populations that have been reported in CCR9−/− mice.
eferences
[1] Zabel BA, Agace WW,  Campbell JJ, Heath HM,  Parent D, Roberts AL, et al.
G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selec-
tively expressed on intestinal homing T lymphocytes, mucosal lymphocytes,
and thymocytes and is required for thymus-expressed chemokine-mediated
chemotaxis. J Exp Med  1999;190(9):1241–56.
[2] Wendland M,  Czeloth N, Mach N, Malissen B, Kremmer E, Pabst O, et al. CCR9 is
a  homing receptor for plasmacytoid dendritic cells to the small intestine. Proc
Natl Acad Sci USA 2007;104(15):6347–52.
[3] Wurbel MA,  Philippe JM,  Nguyen C, Victorero G, Freeman T, Wooding P, et al.
The chemokine TECK is expressed by thymic and intestinal epithelial cells and
attracts double- and single-positive thymocytes expressing the TECK receptor
CCR9. Eur J Immunol 2000;30(1):262–71.
[4] Wurbel MA,  Malissen M,  Guy-Grand D, Malissen B, Campbell JJ. Impaired accu-
mulation of antigen-speciﬁc CD8 lymphocytes in chemokine CCL25-deﬁcient
intestinal epithelium and lamina propria. J Immunol 2007;178(12):7598–606.
[ Letters 151 (2013) 44– 47 47
[5] Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC. CCR9 expression
deﬁnes tolerogenic plasmacytoid dendritic cells able to suppress acute graft-
versus-host disease. Nat Immunol 2008;9(11):1253–60.
[6]  Cassani B, Villablanca EJ, Quintana FJ, Love PE, Lacy-Hulber A, Blaner WS,
et al. T cells that express integrin 47 and CCR9 are required for induc-
tion of oral immune tolerance in mice. Gastroenterology 2011;141(6):
2109–18.
[7] Keshav S, Johnson D, Schall TJ, Bekker P. Chemokine receptor antagonist
CCX282-B (Traﬁcet-EN) maintained remission of Crohn’s disease in PROTECT-1
study. Gastroenterology 2010;138(5):S1–86.
[8] Walters MJ,  Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, et al. Character-
ization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine
receptor CCR9, for treatment of inﬂammatory bowel disease. J Pharmacol Exp
Ther 2010;335(1):61–9.
[9] Apostolaki M,  Manoloukos M,  Roulis M,  Wurbel MA,  Müller W,  Papadakis
KA, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair
CCL25/CCR9 in modeled TNF-dependent Crohn’s disease. Gastroenterology
2008;134(7):2025–35.
10] Wermers JD, McNamee EN, Wurbel MA,  Jedlicka P, Rivera-Nieves. J.
The chemokine receptor CCR9 is required for the T-cell-mediated
regulation  of chronic ileitis in mice. Gastroenterology 2011;140(5):
1526–35.
11] Lehtimäki S, Tillander S, Puustinen A, Matikainen S, Nyman T, Fyhrquist
N, et al. Absence of CCR4 exacerbates skin inﬂammation in an oxazolone-
induced contact hypersensitivity model. J Invest Dermatol 2010;130(12):
2743–51.
12] Yokoyama K, Ishikawa N, Igarashi S, Kawano N, Masuda N, Hat-
tori  K, et al. CCR4 antagonists: synthesis, evaluation, and docking
study  of 2,4-diaminoquinazolines. Bioorg Med  Chem 2008;16(17):
7968–74.
13] Wurbel MA, McIntire MG,  Dwyer P, Fiebiger E. CCL25/CCR9 interactions regu-
late large intestinal inﬂammation in a murine model of acute colitis. PLoS ONE
2011;25:e16442.14]  Wurbel MA,  Malissen M,  Guy-Grand D, Meffre E, Nussenzweig MC, Richelme
M, Carrier A, Malissen B. Mice lacking the CCR9 CC-chemokine receptor
show a mild impairment of early T- and B-cell development and a reduc-
tion in T-cell receptor gammadelta (+) gut intraepithelial lymphocytes. Blood
2001;98(9):2626–32.
